Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 2/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL690215 | 1.00 | ATM (0.59) | ATMPIK3CDGAAALDH1A1ACE | |
| SCHEMBL3674503 | 1.00 | ATM (0.59) | ATMPIK3CDGAAALDH1A1ACE | |
| SCHEMBL19080644 | 1.00 | ATM (0.59) | ATMPIK3CDGAAALDH1A1ACE | |
| SCHEMBL689912 | 1.00 | ATM (0.59) | ATMPIK3CDGAAALDH1A1ACE | |
| SCHEMBL1303907 | 1.00 | ATM (0.59) | ATMPIK3CDGAAALDH1A1ACE | |
| SCHEMBL7882438 | 1.00 | ATM (0.59) | ATMPIK3CDGAAALDH1A1ACE | |
| SCHEMBL8989612 | 1.00 | ATM (0.59) | ATMPIK3CDGAAALDH1A1ACE | |
| SCHEMBL589712 | 1.00 | ATM (0.59) | ATMPIK3CDGAAALDH1A1ACE | |
| Hydrochloric Acid SCHEMBL350474 | 0.98 | ATM (0.57) | ATMPIK3CDGAAALDH1A1ACE | |
| Hydrochloric Acid SCHEMBL2147938 | 0.98 | ATM (0.57) | ATMPIK3CDGAAALDH1A1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0912172-B1 | COMBINATION OF CIS-4-HYDROXY-L-PROLINE AND N-METHYL-CIS-4-HYDROXY-L-PROLINE FOR USE AS A THERAPEUTIC AGENT, IN PARTICULAR IN CANCER TREATMENT | HOERRMANN WILHELM (DE) | 2000-09-06 | — | — | EP | claimed |
| US-6066665-A | Combination of cis-4-hydroxy-L-proline and N-methyl-cis-4-hydroxy-L-proline for use as a therapeutic agent, in particular in cancer treatment | HOERRMANN WILHELM (DE) | 2000-05-23 | — | — | US | claimed |
| EP-0912172-A1 | COMBINATION OF CIS-4-HYDROXY-L-PROLINE AND N-METHYL-CIS-4-HYDROXY-L-PROLINE FOR USE AS A THERAPEUTIC AGENT, IN PARTICULAR IN CANCER TREATMENT | Hoerrmann, Wilhelm, Dr. (DE) | 1999-05-06 | — | — | EP | claimed |
| WO-1997033578-A1 | COMBINATION OF CIS-4-HYDROXY-L-PROLINE AND N-METHYL-CIS-4-HYDROXY-L-PROLINE FOR USE AS A THERAPEUTIC AGENT, IN PARTICULAR IN CANCER TREATMENT | HOERRMANN WILHELM (DE) | 1997-09-18 | — | — | WO | claimed |
| EP-0223850-A1 | MEDICINES WHICH CONTAIN DERIVATIVES OF PROLINE OR HYDROXYPROLINE. | HOERMANN WILHELM | 1987-06-03 | — | — | EP | claimed |
| WO-1986007053-A1 | MEDICINES WHICH CONTAIN DERIVATIVES OF PROLINE OR HYDROXYPROLINE | HOERRMANN WILHELM (DE) | 1986-12-04 | — | — | WO | claimed |
| US-20250295798-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, AND MEDICAL USE THEREOF | BEIGENE SWITZERLAND GMBH (CH) | 2025-09-25 | — | — | US | disclosed |
| EP-4594327-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, AND MEDICAL USE THEREOF | BeiGene Switzerland GmbH (CH) | 2025-08-06 | — | — | EP | disclosed |
| CN-119948031-A | Ligand-drug conjugates of isatecan analogs and medical uses thereof | 广州百济神州生物制药有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20240376073-A1 | QUATERNARY AMMONIUM CATION SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN-LA ROCHE INC. (US) | 2024-11-14 | — | — | US | disclosed |
| WO-2024067811-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, AND MEDICAL USE THEREOF | BEIGENE, LTD. (KY) | 2024-04-04 | — | — | WO | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| WO-2023019430-A1 | COMPOUNDS AS IMMUNOMODULATORS OF PD-L1 INTERACTIONS | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-02-23 | — | — | WO | disclosed |
| EP-0912172-A1 | COMBINATION OF CIS-4-HYDROXY-L-PROLINE AND N-METHYL-CIS-4-HYDROXY-L-PROLINE FOR USE AS A THERAPEUTIC AGENT, IN PARTICULAR IN CANCER TREATMENT | Hoerrmann, Wilhelm, Dr. (DE) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997033578-A1 | COMBINATION OF CIS-4-HYDROXY-L-PROLINE AND N-METHYL-CIS-4-HYDROXY-L-PROLINE FOR USE AS A THERAPEUTIC AGENT, IN PARTICULAR IN CANCER TREATMENT | HOERRMANN WILHELM (DE) | 1997-09-18 | — | — | WO | disclosed |
| WO-1997033578-A1 | COMBINATION OF CIS-4-HYDROXY-L-PROLINE AND N-METHYL-CIS-4-HYDROXY-L-PROLINE FOR USE AS A THERAPEUTIC AGENT, IN PARTICULAR IN CANCER TREATMENT | HOERRMANN WILHELM (DE) | 1997-09-18 | — | — | WO | disclosed |
| US-5665371-A | SIDE EFFECT REDUCTION | HOERRMANN WILHELM (DE) | 1997-09-09 | — | — | US | disclosed |
| EP-0223850-B1 | MEDICINES WHICH CONTAIN DERIVATIVES OF PROLINE OR HYDROXYPROLINE | Hoerrmann, Wilhelm, Dr. (DE) | 1990-04-11 | — | — | EP | disclosed |
| EP-0223850-A1 | MEDICINES WHICH CONTAIN DERIVATIVES OF PROLINE OR HYDROXYPROLINE. | HOERMANN WILHELM | 1987-06-03 | — | — | EP | disclosed |
| WO-1986007053-A1 | MEDICINES WHICH CONTAIN DERIVATIVES OF PROLINE OR HYDROXYPROLINE | HOERRMANN WILHELM (DE) | 1986-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295798-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, AND MEDICAL USE THEREOF | SLC10A1, ERBB3, SLC10A2 | ATM 2576/4885PIK3CD 4024/4885GAA 2267/4885 |
| US-20240376073-A1 | QUATERNARY AMMONIUM CATION SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CFTR, HRH1, HRH4 | ATM 2562/4885PIK3CD 2003/4885GAA 797/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | ATM 234/4885PIK3CD 2841/4885GAA 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.